Lysophosphatidic acid is a bioactive mediator in ovarian cancer
| Autor: | Janos L. Tanyi, Ruthie Lapushin, Yutaka Hasegawa, Shuangxing Yu, Astrid Eder, Robert B. Jaffe, Xianjun Fang, Michèl Schummer, Ramona Swaby, Gordon B. Mills, Jim Erickson, Muling Mao, Fazal H. Tabassam |
|---|---|
| Rok vydání: | 2002 |
| Předmět: |
Ovarian Neoplasms
LPAR3 Cell type G protein Cell growth Receptors Cell Surface Cell Biology Biology medicine.disease Receptors G-Protein-Coupled Cell biology chemistry.chemical_compound Mediator chemistry Reference Values Lysophosphatidic acid medicine Humans Female lipids (amino acids peptides and proteins) Lysophospholipids Receptors Lysophosphatidic Acid Ovarian cancer Receptor Molecular Biology |
| Zdroj: | Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids. 1582:257-264 |
| ISSN: | 1388-1981 |
| Popis: | Lysophosphatidic acid (LPA) is a naturally occurring phospholipid that exhibits pleiotrophic biological activities, ranging from rapid morphological changes to long-term cellular effects such as induction of gene expression and stimulation of cell proliferation and survival on a wide spectrum of cell types. LPA binds and activates distinct members of the Edg/LP subfamily of G protein-coupled receptors that link to multiple G proteins including G(i), G(q) and G(12/13) to elicit cellular responses. LPA plays a critical role as a general growth, survival and pro-angiogenic factor, in the regulation of physiological and pathophysiological processes in vivo and in vitro. Our previous work indicates that abnormalities in LPA metabolism and function in ovarian cancer patients may contribute to the initiation and progression of the disease. Thus, LPA could be a potential target for cancer therapy. This review summarizes evidence that implicates LPA in the pathophysiology of human ovarian cancer and likely other types of human malignancies. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect